Dr. Luis E. Raez(@LuisRaezMD) 's Twitter Profile Photo

These are good news for our patients wiht EGFR tumors we need more studies with uncommon mutations and its good to know that osimertinib is an option for them, there is not a lot of experience in compound mutations yet EGFR Resisters EGFR Resisters Research Summit EGFRm NSCLC EGFR Positive UK

account_circle
Stephen V Liu, MD(@StephenVLiu) 's Twitter Profile Photo

How can we target drug tolerant persistent cell populations in NSCLC? Dr. Regan Memmott describes a trial exploring the beta catenin inhibitor tegavivint with osimertinib EGFR Resisters Research Summit.

How can we target drug tolerant persistent cell populations in #EGFR NSCLC? Dr. Regan Memmott describes a trial exploring the beta catenin inhibitor tegavivint with osimertinib @EGFRSummit.
account_circle